246 related articles for article (PubMed ID: 24051434)
1. Tolerability of intramuscular and intradermal delivery by CELLECTRA(®) adaptive constant current electroporation device in healthy volunteers.
Diehl MC; Lee JC; Daniels SE; Tebas P; Khan AS; Giffear M; Sardesai NY; Bagarazzi ML
Hum Vaccin Immunother; 2013 Oct; 9(10):2246-52. PubMed ID: 24051434
[TBL] [Abstract][Full Text] [Related]
2. A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation.
Hannaman D; Dupuy LC; Ellefsen B; Schmaljohn CS
Vaccine; 2016 Jun; 34(31):3607-12. PubMed ID: 27206386
[TBL] [Abstract][Full Text] [Related]
3. Enhanced immunogenicity and protective efficacy of a tetravalent dengue DNA vaccine using electroporation and intradermal delivery.
Williams M; Ewing D; Blevins M; Sun P; Sundaram AK; Raviprakash KS; Porter KR; Sanders JW
Vaccine; 2019 Jul; 37(32):4444-4453. PubMed ID: 31279565
[TBL] [Abstract][Full Text] [Related]
4. Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers.
Tebas P; Kraynyak KA; Patel A; Maslow JN; Morrow MP; Sylvester AJ; Knoblock D; Gillespie E; Amante D; Racine T; McMullan T; Jeong M; Roberts CC; Park YK; Boyer J; Broderick KE; Kobinger GP; Bagarazzi M; Weiner DB; Sardesai NY; White SM
J Infect Dis; 2019 Jul; 220(3):400-410. PubMed ID: 30891607
[TBL] [Abstract][Full Text] [Related]
5. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Bråve A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandström E; Wahren B
PLoS One; 2015; 10(6):e0131748. PubMed ID: 26121679
[TBL] [Abstract][Full Text] [Related]
6. Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP
Edupuganti S; C De Rosa S; Elizaga M; Lu Y; Han X; Huang Y; Swann E; Polakowski L; A Kalams S; Keefer M; Maenza J; C Wise M; Yan J; Morrow MP; Khan AS; Boyer JD; Humeau L; White S; Sardesai NY; Bagarazzi ML; Gilbert PB; Kublin JG; Corey L; Weiner DB; On Behalf Of The Hvtn Study Team ; The Niaid-Funded Hiv Vaccine Trials Network
Vaccines (Basel); 2020 Dec; 8(4):. PubMed ID: 33297341
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y
Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318
[TBL] [Abstract][Full Text] [Related]
8. A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle.
Lin F; Shen X; McCoy JR; Mendoza JM; Yan J; Kemmerrer SV; Khan AS; Weiner DB; Broderick KE; Sardesai NY
Vaccine; 2011 Sep; 29(39):6771-80. PubMed ID: 21199706
[TBL] [Abstract][Full Text] [Related]
9. Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses.
Jiang J; Ramos SJ; Bangalore P; Fisher P; Germar K; Lee BK; Williamson D; Kemme A; Schade E; McCoy J; Muthumani K; Weiner DB; Humeau LM; Broderick KE
Vaccine; 2019 Jun; 37(29):3832-3839. PubMed ID: 31174938
[TBL] [Abstract][Full Text] [Related]
10. Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques.
Kulkarni V; Rosati M; Bear J; Pilkington GR; Jalah R; Bergamaschi C; Singh AK; Alicea C; Chowdhury B; Zhang GM; Kim EY; Wolinsky SM; Huang W; Guan Y; LaBranche C; Montefiori DC; Broderick KE; Sardesai NY; Valentin A; Felber BK; Pavlakis GN
Hum Vaccin Immunother; 2013 Oct; 9(10):2081-94. PubMed ID: 23811579
[TBL] [Abstract][Full Text] [Related]
11. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.
Vasan S; Hurley A; Schlesinger SJ; Hannaman D; Gardiner DF; Dugin DP; Boente-Carrera M; Vittorino R; Caskey M; Andersen J; Huang Y; Cox JH; Tarragona-Fiol T; Gill DK; Cheeseman H; Clark L; Dally L; Smith C; Schmidt C; Park HH; Kopycinski JT; Gilmour J; Fast P; Bernard R; Ho DD
PLoS One; 2011; 6(5):e19252. PubMed ID: 21603651
[TBL] [Abstract][Full Text] [Related]
12. Optimization of electroporation-enhanced intradermal delivery of DNA vaccine using a minimally invasive surface device.
Lin F; Shen X; Kichaev G; Mendoza JM; Yang M; Armendi P; Yan J; Kobinger GP; Bello A; Khan AS; Broderick KE; Sardesai NY
Hum Gene Ther Methods; 2012 Jun; 23(3):157-68. PubMed ID: 22794496
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of intradermal delivery of hepatitis B booster vaccine using the novel drug delivery device VAX-ID™.
Van Mulder TJS; Withanage K; Beyers KCL; Vankerckhoven VVJ; Theeten H; Van Damme P
Vaccine; 2019 Jan; 37(4):581-586. PubMed ID: 30587432
[TBL] [Abstract][Full Text] [Related]
14. Electroporation of a nanoparticle-associated DNA vaccine induces higher inflammation and immunity compared to its delivery with microneedle patches in pigs.
Bernelin-Cottet C; Urien C; McCaffrey J; Collins D; Donadei A; McDaid D; Jakob V; Barnier-Quer C; Collin N; Bouguyon E; Bordet E; Barc C; Boulesteix O; Leplat JJ; Blanc F; Contreras V; Bertho N; Moore AC; Schwartz-Cornil I
J Control Release; 2019 Aug; 308():14-28. PubMed ID: 31265882
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability and efficacy of intradermal rabies immunization with DebioJect™.
Vescovo P; Rettby N; Ramaniraka N; Liberman J; Hart K; Cachemaille A; Piveteau LD; Zanoni R; Bart PA; Pantaleo G
Vaccine; 2017 Mar; 35(14):1782-1788. PubMed ID: 28317660
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.
Gorse GJ; Falsey AR; Johnson CM; Morrison D; Fried DL; Ervin JE; Greenberg DP; Ozol-Godfrey A; Landolfi V; Tsang PH
Vaccine; 2013 Dec; 31(50):6034-40. PubMed ID: 24055306
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation.
Bråve A; Gudmundsdotter L; Sandström E; Haller BK; Hallengärd D; Maltais AK; King AD; Stout RR; Blomberg P; Höglund U; Hejdeman B; Biberfeld G; Wahren B
Vaccine; 2010 Nov; 28(51):8203-9. PubMed ID: 20951666
[TBL] [Abstract][Full Text] [Related]
18. BTX AgilePulse(TM) system is an effective electroporation device for intramuscular and intradermal delivery of DNA vaccine.
Davtyan H; Hovakimyan A; Zagorski K; Davtyan A; Petrushina I; Agdashian D; Murthy V; Cribbs DH; Agadjanyan MG; Ghochikyan A
Curr Gene Ther; 2014; 14(3):190-9. PubMed ID: 24867066
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes.
Epstein JE; Gorak EJ; Charoenvit Y; Wang R; Freydberg N; Osinowo O; Richie TL; Stoltz EL; Trespalacios F; Nerges J; Ng J; Fallarme-Majam V; Abot E; Goh L; Parker S; Kumar S; Hedstrom RC; Norman J; Stout R; Hoffman SL
Hum Gene Ther; 2002 Sep; 13(13):1551-60. PubMed ID: 12228010
[TBL] [Abstract][Full Text] [Related]
20. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery.
Best SR; Peng S; Juang CM; Hung CF; Hannaman D; Saunders JR; Wu TC; Pai SI
Vaccine; 2009 Sep; 27(40):5450-9. PubMed ID: 19622402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
